Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation

Background Anti-coagulation is required in patients with left ventricular assist devices (LVADs). We evaluated the feasibility of low-molecular-weight heparin (LMWH) for initiation of anti-coagulation and transitioning to oral anti-coagulation after LVAD implantation. Methods This single-center stud...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of heart and lung transplantation 2014, Vol.33 (1), p.88-93
Hauptverfasser:	Sandner, Sigrid E., MD, Riebandt, Julia, MD, Haberl, Thomas, MD, Mahr, Stephane, MD, Rajek, Angela, MD, Schima, Heinrich, PhD, Wieselthaler, George M., MD, Laufer, Guenther, MD, Zimpfer, Daniel, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged anti-coagulation Anticoagulants - adverse effects Anticoagulants - therapeutic use Cohort Studies Feasibility Studies Female heart failure Heart Failure - therapy Heart-Assist Devices - adverse effects Hemorrhage - epidemiology Hemorrhage - etiology Heparin, Low-Molecular-Weight - adverse effects Heparin, Low-Molecular-Weight - therapeutic use Humans Incidence low-molecular-weight Male Middle Aged Outcome Assessment (Health Care) Retrospective Studies Risk Factors Surgery Thrombosis - etiology Thrombosis - prevention & control Treatment Outcome ventricular assist device Ventricular Dysfunction, Left - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!